Innovent Biologics Inc
Change company Symbol lookup
Select an option...
IVBXF Innovent Biologics Inc
STEM Stem Inc
ZIM ZIM Integrated Shipping Services Ltd
METC Ramaco Resources Inc
NVTS Navitas Semiconductor Corp
TRIP Tripadvisor Inc
RKT Rocket Companies Inc
BBVA Banco Bilbao Vizcaya Argentaria SA
F Ford Motor Co
AVLR Avalara Inc
Go


Based in China
Company profile

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Price
Delayed
$4.67
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 0 shares is on pace to be much lighter than IVBXF's 10-day average volume of 10,693 shares.

0

Amazon Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2022 to Discuss Your Rights - AMZN

5:45 pm ET June 30, 2022 (Newsfile) Print

New York, New York--(Newsfile Corp. - June 30, 2022) - Levi & Korsinsky, LLP notifies investors in Amazon.com, Inc. ("Amazon" or the "Company") (NASDAQ: AMZN) of a class action securities lawsuit.

The lawsuit on behalf of Amazon investors has been commenced in the the United States District Court for the Western District of Washington. Affected investors purchased or otherwise acquired certain Amazon.com, Inc. securities between February 1, 2019 and April 5, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/amazon-com-inc-loss-submission-form?prid=29445&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/129703_251798_logo.jpg





Cannot view this video? Visit:

https://www.youtube.com/watch?v=kP1SG0t7ivI

Amazon.com, Inc. NEWS - AMZN NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the defendants' public statements throughout the class period were materially false and/or misleading.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Amazon during the relevant timeframe, you have until July 5, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/amazon-com-inc-loss-submission-form?prid=29445&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129703

comtex tracking

COMTEX_409500028/2523/2022-06-30T17:45:02

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.